Top Page
Clinigence Holdings
(NASDAQ:NUTX)
Clinigence Holdings (NUTX) vs. SPDR S&P 500 ETF (SPY)
Clinigence Holdings Business Overview & Revenue Model
Clinigence Holdings Earnings Call Summary
Clinigence Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 981.20M | 479.95M | 247.65M | 219.29M | 331.53M | 274.03M |
| Gross Profit | 539.77M | 196.26M | 34.77M | 15.42M | 179.28M | 157.61M |
| EBITDA | 361.94M | 148.65M | -14.58M | -394.03M | 183.45M | 158.07M |
| Net Income | 114.07M | 52.18M | -45.79M | -424.78M | 132.59M | 105.97M |
Balance Sheet | ||||||
| Total Assets | 964.52M | 655.32M | 398.25M | 431.75M | 394.65M | 308.55M |
| Cash, Cash Equivalents and Short-Term Investments | 166.05M | 43.58M | 22.00M | 34.26M | 36.12M | 25.51M |
| Total Debt | 358.60M | 340.30M | 275.76M | 267.20M | 178.55M | 150.12M |
| Total Liabilities | 526.49M | 453.43M | 319.14M | 311.42M | 203.07M | 161.19M |
| Stockholders Equity | 317.17M | 146.34M | 61.45M | 95.86M | 114.65M | 85.81M |
Cash Flow | ||||||
| Free Cash Flow | 224.03M | 20.85M | -8.24M | 35.97M | 136.51M | 25.48M |
| Operating Cash Flow | 224.79M | 23.15M | 1.26M | 50.61M | 173.43M | 86.67M |
| Investing Cash Flow | -565.25K | -2.67M | -11.24M | -4.34M | -36.98M | -61.19M |
| Financing Cash Flow | -55.14M | 1.09M | -2.27M | -48.13M | -125.85M | -7.97M |
Clinigence Holdings Technical Analysis
Clinigence Holdings Risk Analysis
Clinigence Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $797.71M | 5.85 | 63.86% | ― | 236.03% | ― | |
67 Neutral | $751.20M | 37.11 | 5.87% | 0.49% | 3.68% | 5.62% | |
60 Neutral | $2.37B | ― | -10.12% | ― | 1.92% | 59.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $468.72M | ― | -13.63% | ― | -16.65% | -71.92% | |
45 Neutral | $206.53M | ― | -31.33% | ― | 4.64% | -17.17% | |
42 Neutral | $396.10M | -1.05 | -47.69% | ― | -5.30% | 46.01% |
Clinigence Holdings Corporate Events
On August 20, 2025, Clinigence Holdings received a notice from Nasdaq due to a delay in filing its quarterly report for June 30, 2025, which led to non-compliance with listing requirements. The company submitted a compliance plan on October 15, 2025, and was granted an extension until December 12, 2025, to file the report, with potential delisting if not met. Nutex Health, meanwhile, reported significant growth in patient volume and cash collections for Q3 2025, with an 11.1% increase in patient visits and a 258.8% rise in cash collections compared to the previous year, driven by strategic expansions and improved revenue management.
The most recent analyst rating on (NUTX) stock is a Buy with a $113.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
On September 22, 2025, Nutex Health Inc. announced the appointment of Wesley Bamburg as the new Chief Operating Officer, effective October 13, 2025. Bamburg, with 20 years of experience in healthcare operations and management, is expected to contribute significantly to Nutex Health’s growth and expansion. His expertise in operations, payor contracting, and physician relations will be pivotal as the company continues to strengthen its healthcare delivery model and expand its national presence.
The most recent analyst rating on (NUTX) stock is a Buy with a $99.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
On September 8, 2025, a derivative action was filed on behalf of Nutex Health Inc. in the U.S. District Court for the Southern District of Texas. The lawsuit names the company’s CEO, CFO, President, and current and former board members as defendants, alleging violations of the Securities Exchange Act, breaches of fiduciary duties, and other misconduct. The action seeks damages, restitution, and corporate governance reforms. Nutex Health is currently unable to predict the litigation’s outcome or its financial impact.
The most recent analyst rating on (NUTX) stock is a Buy with a $300.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
On September 2, 2025, Nutex Health, Inc. appointed Michael L. Reed as the Lead Independent Director of its Board of Directors. Reed, who has been a board member since April 2022, will facilitate communication between independent directors and the company’s management, reinforcing Nutex Health’s commitment to strong corporate governance and compliance with Nasdaq’s requirements. This move highlights the company’s dedication to maintaining robust corporate governance practices.
The most recent analyst rating on (NUTX) stock is a Buy with a $300.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
The recent earnings call for Clinigence Holdings Inc. painted a picture of cautious optimism. While the company reported significant revenue growth, improved profitability, and strong patient satisfaction metrics, these positives were tempered by concerns over delayed SEC filings, reliance on arbitration revenue, and potential litigation risks. The overall sentiment suggests a balance between operational success and underlying challenges.
On August 22, 2025, a securities class action complaint was filed against Nutex Health Inc. in the United States District Court for the Southern District of Texas. The complaint, which follows a recent short seller report, names the company’s top executives as defendants and alleges violations of the Securities Exchange Act of 1934. Nutex Health disputes the allegations and plans to defend itself vigorously, though an adverse ruling could significantly impact its financial position or operations.
The most recent analyst rating on (NUTX) stock is a Buy with a $103.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
On August 20, 2025, Nutex Health Inc. received a notice from Nasdaq due to a delayed filing of its Quarterly Report, risking delisting if not resolved by October 20, 2025. The company is actively working to complete its financial filings. Additionally, Nutex Health disclosed that its previously issued financial statements should not be relied upon due to non-cash classification changes, which are being corrected. Despite these challenges, Nutex Health reported significant financial growth for the three and six months ended June 30, 2025, with total revenue increasing by over 200% compared to the previous year, driven by mature hospitals’ performance.
The most recent analyst rating on (NUTX) stock is a Buy with a $103.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.
Nutex Health Inc., headquartered in Houston, Texas, is a healthcare management and operations company that specializes in micro-hospitals and provider networks across the United States. The company operates through two main divisions: a Hospital Division, which manages 24 facilities in 11 states, and a Population Health Management Division, which supports affiliated hospitals and physician groups.
Nutex Health Inc. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The company cites the need for additional time to analyze the classification of certain equity instruments and finalize its financial statements as the primary reasons for the delay. Despite these challenges, Nutex Health is working diligently to complete the review and expects to file the report within the five-calendar day extension period allowed by Rule 12b-25. The company anticipates significant changes in its financial results compared to the previous fiscal year, although specific details are not yet available. Nutex Health remains committed to compliance and transparency, as evidenced by the signature of Jon C. Bates, Chief Financial Officer, on the notification.
The most recent analyst rating on (NUTX) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Clinigence Holdings stock, see the NUTX Stock Forecast page.